BLCM · Bellicum Pharmaceuticals, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00M | $0 | $0 | - | $1.00M | $0 | - | - | $5.00M | $700.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $263.0K | $4.81M | $7.22M | - | $6.85M | $5.09M | $4.49M | - | $6.35M | $6.72M |
| SG&A | $1.51M | $2.26M | $1.44M | - | $1.31M | $1.45M | $1.45M | - | $1.68M | $1.76M |
| Total Operating Expenses | $1.77M | $7.07M | $8.65M | - | $8.16M | $6.54M | $5.94M | - | $8.03M | $8.49M |
| D&A | - | - | $3.0K | - | - | - | $5.0K | - | - | - |
| Operating Income | ($773.0K) | ($7.07M) | ($8.64M) | - | ($7.17M) | ($6.54M) | ($5.94M) | - | ($3.04M) | ($7.79M) |
| Interest Expense | - | - | - | - | $0 | $0 | $0 | - | $0 | $1.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($763.0K) | ($7.35M) | ($8.07M) | - | ($7.21M) | ($4.00M) | ($7.56M) | - | $1.23M | ($2.20M) |
| EPS - Basic | ($0.02) | ($0.24) | ($0.26) | - | ($0.23) | ($0.13) | ($0.25) | - | ($0.18) | ($0.22) |
| EPS - Diluted | ($0.02) | ($0.24) | ($0.26) | - | ($0.23) | ($0.13) | ($0.25) | - | ($0.18) | ($8.55) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.91M | $7.41M | $15.40M | $21.84M | $28.76M | $33.17M | $39.77M | $46.16M | $19.27M | $20.28M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $526.0K | $472.0K | $1.23M | $486.0K | $714.0K | $399.0K | $212.0K | $90.0K | $521.0K | $760.0K |
| Current Assets | $6.85M | $8.71M | $17.24M | $23.80M | $31.27M | $36.59M | $43.42M | $49.13M | $22.34M | $23.91M |
| Total Assets | $6.85M | $8.73M | $17.26M | $23.82M | $31.28M | $36.60M | $43.43M | $49.14M | $22.37M | $23.96M |
| Current Liabilities | - | - | - | $3.77M | - | - | - | $6.71M | $16.50M | $20.14M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.25M | $3.48M | $4.72M | $3.77M | $5.75M | $4.53M | $7.97M | $6.71M | $16.50M | $20.16M |
| Stockholders' Equity | ($27.01M) | ($21.84M) | ($10.02M) | $2.02M | $7.50M | $14.04M | $17.43M | $24.39M | ($12.16M) | ($14.24M) |
| Retained Earnings | ($591.61M) | ($590.84M) | ($583.49M) | ($575.42M) | ($569.23M) | ($562.01M) | ($558.01M) | ($550.45M) | ($552.98M) | ($554.22M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($6.43M) | - | - | - | ($6.38M) | - | - | - |
| Investing Cash Flow | - | - | ($5.0K) | - | - | - | ($7.0K) | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | $0 | - | - | - |
| CapEx | - | - | $5.0K | - | - | - | $7.0K | - | - | - |
| Free Cash Flow | - | - | ($6.43M) | - | - | - | ($6.38M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -77.3% | - | - | - | -716.5% | - | - | - | -60.9% | -1112.4% |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -76.3% | - | - | - | -721.3% | - | - | - | 24.7% | -314.6% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.80 | - | - | - | 0.84 | - | - | - |
| R&D / Revenue | 26.3% | - | - | - | 685.0% | - | - | - | 127.0% | 960.3% |
| SG&A / Revenue | 151.1% | - | - | - | 131.5% | - | - | - | 33.6% | 252.1% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -11.1% | -84.2% | -46.7% | - | -23.1% | -10.9% | -17.4% | - | 5.5% | -9.2% |
| Return on equity | 2.8% | 33.7% | 80.5% | - | -96.2% | -28.5% | -43.4% | - | -10.1% | 15.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | - | - | - | 6.31 | - | - | - | 7.32 | 1.35 | 1.19 |
| Quick ratio | - | - | - | 6.31 | - | - | - | 7.32 | 1.35 | 1.19 |
| Cash ratio | - | - | - | 5.79 | - | - | - | 6.88 | 1.17 | 1.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | -7787.0x |
| Equity multiplier | -0.25 | -0.40 | -1.72 | 11.82 | 4.17 | 2.61 | 2.49 | 2.01 | -1.84 | -1.68 |
| Liabilities / Assets | 0.33 | 0.40 | 0.27 | 0.16 | 0.18 | 0.12 | 0.18 | 0.14 | 0.74 | 0.84 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | 0.00 | 0.00 | - | 0.03 | 0.00 | - | - | 0.22 | 0.03 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.0% | - | - | - | -80.0% | -100.0% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | 113.3% | - | - | - | 157.7% | 24.6% |
| Revenue CAGR (5y) | 27.9% | - | - | - | 51.3% | - | - | - | 113.0% | 47.3% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 89.2% | -8.1% | -45.6% | - | -135.5% | 16.1% | 33.5% | - | 75.3% | 33.8% |
| Net income growth (YoY) | 89.4% | -83.8% | -6.7% | - | - | -81.7% | 32.9% | - | - | 94.9% |
| EPS growth (YoY) | 91.3% | -84.6% | -4.0% | - | -27.8% | 98.5% | 77.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -0.8% | - | - | - | 23.0% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -91.7% | - | - | - | - | 74.7% | 70.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$12.40M totalSupply Agreement And License Revenue$6.20M · 50.0%
License Revenue$5.50M · 44.4%
Supply Agreement$700.0K · 5.6%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BELLICUM PHARMACEUTICALS against the 5 most active filers in the same SIC group.